|By Business Wire||
|January 15, 2014 01:30 PM EST||
Sofemed International, manufacturer of orthopaedic medical devices, recently selected their ERP platform, QAD Enterprise Applications, from QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services. The deployment of QAD Enterprise Applications supported Sofemed International in quickly gaining ISO certification for quality and meeting the software validation requirements of cGMP regulations, a mandatory requirement for the medical device industry.
Sofemed International worked with CSI, QAD's implementation partner, to acquire and establish the solution. "We are pleased to be able to support companies in Tunisia with the full impact of QAD's ERP solution," comments Ilhem BRINI, Business Development Manager with CSI. "Being part of QAD's global team allows us to deliver great strength to our customers."
Since the implementation of QAD Enterprise Application and according to Mr. Yacine Guirat (CEO), Sofemed International has achieved:
- Quality certification according to ISO9001:2008, ISO 13485:2003
- Product certification according to EU Directive 93/42/EEC
- Improved interdepartmental communication and coordination
- Better process monitoring
- Consistent and uniform information (Item and Customer Master data)
- Growth in their subcontracting business producing components for large European manufacturers
QAD Enterprise Applications — Tailored for Regulatory Compliance
QAD Enterprise Applications makes it simpler for medical device makers to achieve regulatory compliance and ensure product integrity by supporting manufacturers in achieving regulatory compliance and validation of Current Good Manufacturing Practices (cGMP), product traceability, post-market safety surveillance, recall management and safety alerts.
Enhanced Traceability in QAD Enterprise Applications Supports Patient Safety
Patient safety is of critical concern for medical device manufacturers. In the case of an adverse event that leads to a product recall, QAD Enterprise Applications enables customers to efficiently manage and evaluate the effectiveness of a recall. It allows customers to trace a recalled item back to its original manufacturing batch or lot and then forward to locate potentially affected finished products still in inventory or the supply chain.
The Effective Enterprise in Life Sciences
QAD enables life sciences companies to meet the critical quality requirements for manufacturing innovative, safe and effective healthcare products in compliance with global regulatory standards. QAD incorporates intuitive, easy to use, industry best practices that can be flexibly deployed either onsite or on demand to support global life sciences companies.
For more information about QAD Enterprise Applications, please visit: www.qad.com.
About QAD – The Effective Enterprise
QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB), is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 30 years, QAD has provided global manufacturing companies with an enterprise resource planning (ERP) system that supports operational requirements; including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD offers flexible deployment options like QAD On Premise software and QAD On Demand software-as-a-service. Customers can operate in a blended environment where some users can be deployed On Premise and some users deployed via On Demand while offering the same end-user experience. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.
“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
About Sofemed International
Created since more than 15 years by two businessmen in metallurgy industry and a team of several doctors in orthopaedics, SOFEMED International is a precursor in development and manufacture of medical equipments in the African and the Arab market, transmitting with pride the tradition to offer ingenious solutions to the orthopaedic surgery. With operations in more than 15 countries, SOFEMED International has been specialised in the development and sales orthopaedic medical. Always keeping a close watch on its market needs, SOFEMED International consolidated its basic experience and know-how by creating a range with complementary and diversified activities.
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2013 ended January 31, 2013, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.